The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis.

Autor:	Kuksis M; Department of Medicine, Queen's University, Kingston, Ontario, Canada., Gao Y; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Tran W; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Hoey C; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Kiss A; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Komorowski AS; Division of Medical Microbiology, McMaster University, Hamilton, Ontario, Canada., Dhaliwal AJ; Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Sahgal A; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Das S; Division of Neurosurgery, St. Michael's Hospital, Toronto, Ontario, Canada., Chan KK; Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.; The Canadian Centre for Applied Research in Cancer Control, Vancouver, British Columbia, Canada., Jerzak KJ; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.; Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Jazyk:	angličtina
Zdroj:	Neuro-oncology [Neuro Oncol] 2021 Jun 01; Vol. 23 (6), pp. 894-904.
DOI:	10.1093/neuonc/noaa285
Abstrakt:	Background: Patients with metastatic breast cancer (MBC) are living longer, but the development of brain metastases often limits their survival. We conducted a systematic review and meta-analysis to determine the incidence of brain metastases in this patient population. Methods: Articles published from January 2000 to January 2020 were compiled from four databases using search terms related to breast cancer, brain metastasis, and incidence. The overall and per patient-year incidence of brain metastases were extracted from studies including patients with human epidermal growth factor receptor-2 positive (HER2+), triple negative, and hormone receptor (HR)+/hormone receptor negative (HER2-) MBC; pooled overall estimates for incidence were calculated using random effects models. Results: 937 articles were compiled, and 25 were included in the meta-analysis. Incidence of brain metastases in patients with HER2+ MBC, triple negative MBC, and HR+/HER2- MBC was reported in 17, 6, and 4 studies, respectively. The pooled cumulative incidence of brain metastases was 31% for the HER2+ subgroup (median follow-up: 30.7 months, IQR: 24.0-34.0), 32% for the triple negative subgroup (median follow-up: 32.8 months, IQR: 18.5-40.6), and 15% among patients with HR+/HER2- MBC (median follow-up: 33.0 months, IQR: 31.9-36.2). The corresponding incidences per patient-year were 0.13 (95% CI: 0.10-0.16) for the HER2+ subgroup, 0.13 (95%CI: 0.09-0.20) for the triple negative subgroup, and only 0.05 (95%CI: 0.03-0.08) for patients with HR+/HER2- MBC. Conclusion: There is a high incidence of brain metastases among patients with HER2+ and triple negative MBC. The utility of a brain metastases screening program warrants investigation in these populations. (© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu